Astrazeneca Share News (AZN)

AstraZeneca to buy 55 pct of cancer firm Acerta for $4.0 bln

LONDON, Dec 17 (Reuters) - AstraZeneca said on Thursday it had agreed to buy a 55 percent stake in privately held biotech firm Acerta Pharma for $4.0 billion to give it access to a new kind of drug for fighting blood cancers. AstraZeneca will pay $2.5 billion upfront, with a further $1.5 bi

AstraZeneca To Pay USD4 Million For Majority Of Acerta Pharma

AstraZeneca buys majority stake in Acerta Pharma to expand oncology portfolio

(ShareCast News) - AstraZeneca has announced it will acquire a 55% stake in Acerta Pharma over its oncology treatment - a deal valued at $4bn (£2.7bn). The deal will give the FTSE 100 pharmaceutical company access to the privately-owned US and Netherlands based biopharmaceutical company's acalabruti

Polar Capital Global Healthcare Trust Managers Affirm Belief In Target

UPDATE 1-AstraZeneca boosts respiratory unit with $575 mln Takeda deal

(Adds further details) LONDON, Dec 16 (Reuters) - Britain's AstraZeneca has agreed to buy Takeda Pharmaceutical's respiratory business, including expanded rights to roflumilast, a treatment for chronic obstructive pulmonary disease (COPD). AstraZeneca, which has marketed roflumilast i

AstraZeneca to acquire Takeda Pharmaceutical Company for drug rights

(ShareCast News) - AstraZeneca will acquire the core respiratory business of Takeda Pharmaceutical Company for $575m (£382m). The deal includes the expansion of rights to chronic obstructive pulmonary disease (COPD) treatment roflumilast, also known as Daliresp in the US and Daxas elsewhere. The FT

AstraZeneca boosts respiratory unit with $575 mln Takeda deal

LONDON, Dec 16 (Reuters) - Britain's AstraZeneca has agreed to buy Takeda Pharmaceutical's respiratory business, including expanded rights to roflumilast, a treatment for chronic obstructive pulmonary disease (COPD). AstraZeneca, which has marketed roflumilast in the United States under the

AstraZeneca Snaps Up Takeda's Respiratory Unit For USD575 Million

AstraZeneca investing $800 mln to go local in China

By Ben Hirschler LONDON, Dec 16 (Reuters) - AstraZeneca aims to build up its already strong position in China by making and developing more medicines locally, and will invest more than $800 million in the country over the next 10 years, it said on Wednesday. The British drugmaker's de

Astrazeneca completes disposal of Entocort

(ShareCast News) - AstraZeneca has received a $380m payment from Irish competitor Perrigo as the FTSE 100 company completed the disposal of right for a Crohn's disease medicine. Perrigo last month agreed to buy the US rights from AstraZeneca to sell Entocort capsules and generic Entocort capsules ma

AstraZeneca Sells US Rights For Crohn's Medicine Entocort To Perrigo

UPDATE 2-AstraZeneca chases Acerta to secure next cancer drug winner

* AstraZeneca confirms talks with biotech firm Acerta * Signals determination to build up cancer drug business * "No certainty" that any deal will be agreed (Adds comment on other potential bidders for Acerta) By Ben Hirschler LONDON, Dec 14 (Reuters) - AstraZeneca said

UPDATE 1-AstraZeneca chases Acerta to secure next cancer drug winner

* AstraZeneca confirms talks with biotech firm Acerta * Signals determination to build up cancer drug business * "No certainty" that any deal will be agreed (Adds analyst comment, detail on Acerta drug) By Ben Hirschler LONDON, Dec 14 (Reuters) - AstraZeneca said on Mond

AstraZeneca confirms talks with biotech group Acerta

(ShareCast News) - Pharmaceuticals giant AstraZeneca confirmed that it is exploring potential strategic options with biotech company Acerta Pharma BV. "There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction," AZN said. The statement fol

AstraZeneca confirms talks with cancer drug firm Acerta

LONDON, Dec 14 (Reuters) - AstraZeneca said on Monday it was in talks with privately held cancer drug developer Acerta Pharma, after the Wall Street Journal reported on Friday it was looking to acquire the business for more than $5 billion. "AstraZeneca confirms that it is exploring potenti